MeSCue-Janusys Inc. is a Biotech venture company addressing high unmet medical needs particularly in the field of periodontal and neurodegenerative diseases.
Our company aspires to improve the health of patients by commercially exploiting the therapeutic potential of our novel peptides.
We aim to fundamentally improve the quality of life for patients and helping to reduce overall healthcare costs by providing innovative therapies with our proprietary technologies.
to meet the unmet medical needs by using innovative therapies and diagnostic tools.
to bring innovative science and technology together for the development of effective and tolerable therapy
Janusys incorporated as independent spinoff of AIST*
MeSCue incorporated as independent spinoff of AIST
Janusys selected as one of 100 most innovative Japanese ventures
MeSCue acquired Janusys and became MeSCue-Janusys
Board of Directors
Koichiro Kitamura Ph.D.
President & Chief Executive Officer (CEO)
Naoto Kagiyama Ph.D.
Executive Vice President & Founder
Managment & Scientific Advisors
Waleed Osman, VMD, Ph.D.
Business Development Senior manager
Tai Kubo, Ph.D.
Scientific Advisor, Ex-Deputy Director of "The Molecular Profiling Research Center for Drug Discovery (molprof), AIST"
Michio Oishi, Ph.D.
Scientific Advisor, Chairman of “Kazusa DNA Research Institute”
Shigetaka Asano, MD, Ph.D.
Scientific Advisor, Ex-Director of “The Institute of Medical Science Hospital”, The University of Tokyo